English | Español
English | Español
  • Insurance
  • Marketing
  • Pharmaceuticals
  • Technology/Innovation
  • Regulatory
  • Community

Eli Lilly And Company

Patient Daily | May 25, 2023

Lilly ESG Report Highlights Progress Towards Sustainability Goals

Patient Daily | May 24, 2023

Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine

Patient Daily | May 22, 2023

Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting

Patient Daily | May 9, 2023

Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana

Patient Daily | May 9, 2023

Lilly Declares Second-Quarter 2023 Dividend

Patient Daily | May 9, 2023

Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2

Patient Daily | Apr 26, 2023

Lilly to Divest BAQSIMI to Amphastar

Patient Daily | Apr 26, 2023

Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities

Trending

+ Pharmaceuticals
Patient Daily | Jun 30, 2025

PhRMA public affairs senior director on 340B program: 'PBMs took $140 billion in rebates and fees, driving up American medicine costs'

+ Pharmaceuticals
Patient Daily | Jun 25, 2025

Neurosurgeon at the University of California: ‘340B is being exploited for profit, not patient care’

+ Pharmaceuticals
Patient Daily | Jul 1, 2025

PhRMA chief public affairs officer on 340B drug pricing: ‘Lowering drug prices for U.S. patients starts by reining in middlemen’

  • 1
  • 2
  • 3
  • »
  • Last »


Community
Insurance
Marketing
Pharmaceuticals
Regulatory
Technology/Innovation
About
Contact
© 2025 Patient Daily